The Trailblazer study: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

This is a phase 3 study to evaluate the safety and efficacy of donanemab in participants with early symptomatic Alzheimer's Disease caused by elevated tau protein in the brain. Data suggests that removing this may result in the slowing of Alzheimer's Disease and this drug has shown potential for achieve this. 

You may be eligible to participate if you meet the following criteria: 

• aged 60 to 85 years and 
• have had a gradual change in memory function over 6 months

Visits will include cognitive assessments, blood tests, ECG and MRI scans. 

A study partner who has at least 10 hours of contact with the participant is required to accompany the participant to visits, to provide accurate information about the participant's cognitive and functional abilities over time.